1. Effect of Secukinumab on Patient‐Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1). Issue 12 (December 2016) Authors: Deodhar, Atul A.; Dougados, Maxime; Baeten, Dominique L.; Cheng‐Chung Wei, James; Geusens, Piet; Readie, Aimee; Richards, Hanno B.; Martin, Ruvie; Porter, Brian Journal: Arthritis & rheumatology Issue: Volume 68:Issue 12(2016) Page Start: 2901 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. (19th December 2018) Authors: Braun, Jürgen; Baraliakos, Xenofon; Deodhar, Atul; Poddubnyy, Denis; Emery, Paul; Delicha, Eumorphia M; Talloczy, Zsolt; Porter, Brian Journal: Rheumatology Issue: Volume 58:Number 5(2019) Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 263 Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. (12th April 2019) Authors: McInnes, Iain B; Deodhar, Atul; Gladman, Dafna D; Ren, Mengyuan; Spindeldreher, Sebastian; Pricop, Luminita; Porter, Brian; Safi, Jorge; Shete, Abhijit; Bruin, Gerard Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. (30th May 2018) Authors: van der Heijde, Désirée; Braun, Jürgen; Deodhar, Atul; Baraliakos, Xenofon; Landewé, Robert; Richards, Hanno B; Porter, Brian; Readie, Aimee Journal: Rheumatology Issue: Volume 58:Number 3(2019) Page Start: 388 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 260 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis. (12th April 2019) Authors: Marzo-Ortega, Helena; Deodhar, Atul; Miceli-Richard, Corinne; Baraliakos, Xenofon; Gladman, Dafna D; Martin, Ruvie; Safi, Jorge; Porter, Brian; Shete, Abhijit Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 264 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. (12th April 2019) Authors: Emery, Paul; Baraliakos, Xenofon; Braun, Jürgen; Deodhar, Atul; Poddubnyy, Denis; Delicha, Eumorphia-Maria; Talloczy, Zsolt; Porter, Brian Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. Issue 5 (30th April 2020) Authors: Deodhar, Atul A.; Miceli‐Richard, Corine; Baraliakos, Xenofon; Marzo‐Ortega, Helena; Gladman, Dafna D.; Blanco, Ricardo; Das Gupta, Ayan; Martin, Ruvie; Safi, Jorge; Porter, Brian; Shete, Abhijit; Rosenbaum, James T. Journal: ACR open rheumatology Issue: Volume 2:Issue 5(2020) Page Start: 294 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. FRI0418 SECUKINUMAB PROVIDED SIMILAR EFFICACY IN MALES AND FEMALES WITH ACTIVE ANKYLOSING SPONDYLITIS OVER 52 WEEKS: POST HOC POOLED ANALYSIS OF THE MEASURE TRIALS. (June 2019) Authors: Horst-Bruinsma, Irene van der; Richard, Corinne Miceli; Braun, Juergen; Bao, Weibin; Porter, Brian; Pournara, Effie Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 897 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. FRI0388 SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM. (June 2019) Authors: Deodhar, Atul; Boonen, Annelies; Ferraccioli, Gianfranco; Bosch, Filip van den; Martinez, David; Porter, Brian; Shete, Abhijit; Gilloteau, Isabelle; Yocolly, Aurore; Strand, Vibeke Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 878 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES. (June 2019) Authors: Schett, Georg; Baraliakos, Xenofon; Bosch, Filip van den; Deodhar, Atul; Gensler, Lianne S.; Ǿstergaard, Mikkel; Agawane, Shital; Gupta, Ayan Das; Mpofu, Shephard; Fox, Todd; Winseck, Adam; Shete, Abhijit; Porter, Brian Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 873 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗